Jefferies Group Weighs in on Dova Pharmaceuticals Inc’s FY2022 Earnings (DOVA)
Dova Pharmaceuticals Inc (NASDAQ:DOVA) – Equities researchers at Jefferies Group issued their FY2022 EPS estimates for shares of Dova Pharmaceuticals in a research note issued on Friday. Jefferies Group analyst E. Yang forecasts that the company will post earnings of $4.03 per share for the year. Jefferies Group has a “Buy” rating and a $33.00 price objective on the stock.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.08). During the same period last year, the company posted ($0.41) EPS.
A number of other brokerages also recently commented on DOVA. Leerink Swann upgraded shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price on the stock in a research note on Tuesday, September 26th. BidaskClub downgraded shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Zacks Investment Research downgraded shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Dova Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $32.75.
Shares of Dova Pharmaceuticals (NASDAQ:DOVA) traded up $0.64 during mid-day trading on Monday, reaching $29.19. 599,996 shares of the company’s stock were exchanged, compared to its average volume of 209,040. The company has a market cap of $748.80 and a P/E ratio of -32.80. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $32.75.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new position in shares of Dova Pharmaceuticals during the third quarter valued at approximately $202,000. Laurion Capital Management LP bought a new position in shares of Dova Pharmaceuticals during the second quarter valued at approximately $223,000. Schwab Charles Investment Management Inc. bought a new position in shares of Dova Pharmaceuticals during the third quarter valued at approximately $241,000. Bank of New York Mellon Corp bought a new position in shares of Dova Pharmaceuticals during the third quarter valued at approximately $340,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Dova Pharmaceuticals during the second quarter valued at approximately $382,000. Hedge funds and other institutional investors own 26.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Jefferies Group Weighs in on Dova Pharmaceuticals Inc’s FY2022 Earnings (DOVA)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/01/08/jefferies-group-weighs-in-on-dova-pharmaceuticals-incs-fy2022-earnings-dova.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.